DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018)
DiaMedica Therapeutics' (DMAC) quarterly Gains from Investment Securities came in at $39000.0 in Q1 2018.
DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018) Analysis & Trends
DiaMedica Therapeutics' Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $39000.0 for Q1 2018.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $39000.0 in Q1 2018; TTM through Dec 2018 was $39000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $39000.0, up 533.33% from the prior year.
- Gains from Investment Securities held at $39000.0 in Q1 2018 per DMAC's latest filing.
- Across five years, Gains from Investment Securities topped out at $39000.0 in Q1 2018 and bottomed at $39000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | DiaMedica Therapeutics | 364.72 Mn | 364.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 39,000.00 |
| Mar 31, 2018 | 39,000.00 |